top of page

Key Benefits

Biologic Description

Thymosin Alpha-1 (Tα1) is a biologically active peptide fragment cleaved from the precursor protein prothymosin alpha, which is encoded by the PTMA gene. As a critical immune regulatory peptide, Tα1 is intricately involved in the modulation of cellular immune responses, particularly enhancing the maturation and efficacy of key immune effector cells. Its primary sequence, Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Gly-Glu-Asn-OH, includes 28 amino acids and features an N-terminal acetylation which is pivotal for its stability and functional interaction within the immune system.

 

Tα1 operates through a multifaceted mechanism primarily characterized by the upregulation of T-cell, dendritic cell, and natural killer (NK) cell activity. It enhances the expression of critical components of the T-cell receptor (TCR) signaling pathway, thus facilitating T-cell responsiveness to antigens. This peptide also acts on dendritic cells to promote their maturation, characterized by increased expression of major histocompatibility complex (MHC) class I and II molecules, which are essential for antigen presentation and subsequent T-cell activation.

 

Furthermore, Tα1 influences the cytokine milieu, notably increasing levels of interleukin-12 (IL-12) and interferon-gamma (IFN-γ), which are crucial for initiating and propagating the Th1 immune response against infectious agents and tumor cells. The regulation of these cytokines underscores its role in skewing the immune response towards a cell-mediated immunity, which is vital for effective responses against intracellular pathogens and malignant cells.

 

At the molecular level, Tα1's activities may be mediated through interactions with pattern recognition receptors such as Toll-like receptors (TLRs), possibly TLR9, which facilitate innate immune sensing and subsequent adaptive immune responses. This interaction likely modulates downstream signaling pathways, including the activation of nuclear factor kappa B (NF-κB) and mitogen-activated protein kinase (MAPK) pathways, which play pivotal roles in cytokine production and immune cell regulation.

Dosage Guidelines

Thymosin Alpha-1 (Tα1) dosage and administration guidelines are tailored to the specific condition being treated, the researcher's health status, and the intended therapeutic outcomes.

 

Typically, the standard dose of Tα1 is 1.5 mg administered subcutaneously twice a week, although this may be adjusted based on medical advice and patient response.

 

In more severe scenarios, such as significant infections or as part of cancer adjunct therapy, the dosage may be increased to 2.5 mg twice a week following careful evaluation.

​

The duration of Tα1 therapy can vary significantly. For chronic conditions or as an adjunct to cancer therapy, treatment cycles might extend from several weeks to months, typically involving continuous administration for 4 to 8 weeks at a time. This is followed by a reassessment period to evaluate the treatment's effectiveness and determine the need for continuation.

 

For short-term use, such as enhancing vaccine efficacy, shorter cycles or even single doses might be administered prior to vaccination to boost the immune response. This approach allows for a flexible application of Tα1 to meet diverse therapeutic needs effectively.

1.5-2.5 mg

Twice a Week

4-8 Weeks

Side Effects

Thymosin Alpha-1 (Tα1) is generally well-tolerated, but like all therapeutic treatments, it can have side effects. Commonly reported side effects include mild injection site reactions such as redness, swelling, and discomfort, which typically resolve without intervention. Less frequently, patients may experience fatigue, headache, and muscle aches, which are often transient and diminish as the body adjusts to the treatment.


More serious side effects are rare but can occur, especially in individuals with pre-existing health conditions or those on concurrent medications that may interact with the peptide. These can include autoimmune reactions, where the immune system becomes overly activated, leading to symptoms like fever, joint pain, and in severe cases, organ inflammation. Allergic reactions, though uncommon, are also a potential risk and can manifest as rash, itching, or in extreme cases, anaphylaxis, which requires immediate medical attention.


Due to its immunomodulatory effects, there is a theoretical risk of infection; thus, patients with compromised immune systems should be monitored closely while receiving Tα1 therapy. Patients are encouraged to report any unusual or persistent symptoms to their healthcare provider, who can adjust the treatment regimen as necessary to mitigate side effects and ensure safety throughout the course of therapy.

References:

  1. Garaci, E., Pica, F., Sinibaldi-Vallebona, P., Pierimarchi, P., & Favalli, C. (2007). Thymosin alpha 1 in the treatment of cancer: from basic research to clinical application. International Journal of Immunopathology and Pharmacology, 20(3), 349-354.

  2. Liu, F., Tong, J., Yu, H., & Zheng, H. (2019). Efficacy and safety of thymosin alpha 1 for sepsis: a systematic review and meta-analysis. International Immunopharmacology, 68, 319-327.

  3. Romani, L., Bistoni, F., Gaziano, R., Bozza, S., Montagnoli, C., Perruccio, K. & Puccetti, P. (2004). Thymosin alpha 1 activates dendritic cells for antifungal Th1 resistance through toll-like receptor signaling. Blood, 103(11), 4232-4239.

  4. Serafino, A., Vallebona, P. S., Andreola, F., Zonfrillo, M., Mercuri, L., Federici, M. & Pierimarchi, P. (2011). Stimulatory effect of EMAPII on the migratory and invasive capacity of various tumor cell lines and the role of thymosin beta 4. International Journal of Molecular Medicine, 27(6), 769-778.

bottom of page